Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Does surgical treatment of atypical endometrial hyperplasia require referral to a gynecologic oncologist?

Shalowitz DI, Goodwin A, Schoenbachler N.

Am J Obstet Gynecol. 2019 May;220(5):460-464. doi: 10.1016/j.ajog.2018.12.010. Epub 2018 Dec 7.

PMID:
30527944
2.

Access to gynecologic oncology care and the network adequacy standard.

Shalowitz DI, Huh WK.

Cancer. 2018 Jul 1;124(13):2677-2679. doi: 10.1002/cncr.31392. Epub 2018 May 16. No abstract available.

PMID:
29767846
3.

Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.

Venigalla S, Chowdhry AK, Shalowitz DI.

Gynecol Oncol. 2018 Jun;149(3):531-538. doi: 10.1016/j.ygyno.2018.03.046. Epub 2018 Mar 17.

PMID:
29559170
4.

Cancer care delivery research in gynecologic oncology.

Shalowitz DI, Cohn DE.

Gynecol Oncol. 2018 Mar;148(3):445-448. doi: 10.1016/j.ygyno.2017.12.027. Epub 2018 Jan 10. No abstract available.

PMID:
29331372
5.

Are patients willing to travel for better ovarian cancer care?

Shalowitz DI, Nivasch E, Burger RA, Schapira MM.

Gynecol Oncol. 2018 Jan;148(1):42-48. doi: 10.1016/j.ygyno.2017.10.018. Epub 2017 Nov 1.

PMID:
29079037
6.

Barriers to accessing urethroplasty.

Consolo MJ, Syed KK, Robison C, McFadden J, Shalowitz DI, Brown GA, Sussman DO, Figler BD.

Rev Urol. 2016;18(4):188-193. doi: 10.3909/riu0731.

7.

Survival implications of time to surgical treatment of endometrial cancers.

Shalowitz DI, Epstein AJ, Buckingham L, Ko EM, Giuntoli RL 2nd.

Am J Obstet Gynecol. 2017 Mar;216(3):268.e1-268.e18. doi: 10.1016/j.ajog.2016.11.1050. Epub 2016 Dec 9.

PMID:
27939327
8.

Reply.

Shalowitz DI, Spillman MA, Morgan MA.

Am J Obstet Gynecol. 2016 Dec;215(6):811. doi: 10.1016/j.ajog.2016.07.054. Epub 2016 Aug 2. No abstract available.

PMID:
27496688
9.

Non-surgical management of ovarian cancer: Prevalence and implications.

Shalowitz DI, Epstein AJ, Ko EM, Giuntoli RL 2nd.

Gynecol Oncol. 2016 Jul;142(1):30-37. doi: 10.1016/j.ygyno.2016.04.026. Epub 2016 May 5.

PMID:
27107721
10.

Interactions with industry under the Sunshine Act: an example from gynecologic oncology.

Shalowitz DI, Spillman MA, Morgan MA.

Am J Obstet Gynecol. 2016 Jun;214(6):703-7. doi: 10.1016/j.ajog.2016.02.035. Epub 2016 Feb 20.

PMID:
26902988
11.

Suggestibility of Oncologists' Clinical Estimates.

Shalowitz DI, Schorge JO.

JAMA Oncol. 2015 May;1(2):251-3. doi: 10.1001/jamaoncol.2015.62. No abstract available.

PMID:
26181033
12.

Teleoncology for gynecologic cancers.

Shalowitz DI, Smith AG, Bell MC, Gibb RK.

Gynecol Oncol. 2015 Oct;139(1):172-7. doi: 10.1016/j.ygyno.2015.06.042. Epub 2015 Jul 5. Review.

PMID:
26151077
13.

Geographic access to gynecologic cancer care in the United States.

Shalowitz DI, Vinograd AM, Giuntoli RL 2nd.

Gynecol Oncol. 2015 Jul;138(1):115-20. doi: 10.1016/j.ygyno.2015.04.025. Epub 2015 Apr 25.

PMID:
25922191
14.

Typical-use contraception and pharmaceutical research.

Winkelman WD, Shalowitz DI.

Am J Bioeth. 2012;12(7):42-3. doi: 10.1080/15265161.2012.680546. No abstract available.

PMID:
22694035
15.

Research in pregnancy: back to first principles.

Shalowitz DI, Ecker JL.

Am J Bioeth. 2011 May;11(5):56-7. doi: 10.1080/15265161.2011.560347. No abstract available.

PMID:
21534155
16.

Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers.

Christensen KD, Roberts JS, Shalowitz DI, Everett JN, Kim SY, Raskin L, Gruber SB.

Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):522-9. doi: 10.1158/1055-9965.EPI-10-1045. Epub 2011 Feb 9.

17.

Returning individual research results: development of a cancer genetics education and risk communication protocol.

Roberts JS, Shalowitz DI, Christensen KD, Everett JN, Kim SY, Raskin L, Gruber SB.

J Empir Res Hum Res Ethics. 2010 Sep;5(3):17-30. doi: 10.1525/jer.2010.5.3.17.

18.

Building a better advance directive: next steps.

Shalowitz DI, Silveira MJ.

Am J Bioeth. 2010 Apr;10(4):34-6. doi: 10.1080/15265161003650502. No abstract available.

PMID:
20379919
19.

Ethical analysis of communicating the risk of iatrogenic Creutzfeldt-Jakob disease.

Shalowitz DI, Barnosky A, Smith LB.

Infect Control Hosp Epidemiol. 2009 Aug;30(8):805-6. doi: 10.1086/599004. No abstract available.

PMID:
19591583
20.

Should informed consent for cancer treatment include a discussion about hospital outcome disparities?

Housri N, Weil RJ, Shalowitz DI, Koniaris LG.

PLoS Med. 2008 Oct 21;5(10):e214. doi: 10.1371/journal.pmed.0050214.

21.

The search for clarity in communicating research results to study participants.

Shalowitz DI, Miller FG.

J Med Ethics. 2008 Sep;34(9):e17. doi: 10.1136/jme.2008.025122.

PMID:
18757617
22.

Communicating the results of clinical research to participants: attitudes, practices, and future directions.

Shalowitz DI, Miller FG.

PLoS Med. 2008 May 13;5(5):e91. doi: 10.1371/journal.pmed.0050091. No abstract available.

23.

How should treatment decisions be made for incapacitated patients, and why?

Shalowitz DI, Garrett-Mayer E, Wendler D.

PLoS Med. 2007 Mar;4(3):e35. No abstract available.

24.

The accuracy of surrogate decision makers: a systematic review.

Shalowitz DI, Garrett-Mayer E, Wendler D.

Arch Intern Med. 2006 Mar 13;166(5):493-7. Review.

PMID:
16534034
25.

Disclosing individual results of clinical research: implications of respect for participants.

Shalowitz DI, Miller FG.

JAMA. 2005 Aug 10;294(6):737-40. No abstract available.

PMID:
16091577
26.

Shared decision-making and the lower literate patient.

Shalowitz DI, Wolf MS.

J Law Med Ethics. 2004 Winter;32(4):759-64. No abstract available.

PMID:
15807364

Supplemental Content

Loading ...
Support Center